Apellis Pharmaceuticals (APLS) Stock Price
Apellis Pharmaceuticals Price
Revenue has compounded at 32.0% per year over the past 5 years to 1.00 B USD. Apellis Pharmaceuticals's net margin stands at 2.2%, up from -1,121.3% several years earlier. Analysts set a median price target of 32.13 USD, implying 21.7% below the current price. Of 28 analysts, 20 rate the stock a buy — an overall Buy consensus.
Apellis Pharmaceuticals stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Apellis Pharmaceuticals business model & stock analysis
Frequently asked questions about Apellis Pharmaceuticals
The business model of Apellis Pharmaceuticals Inc is focused on developing and commercializing novel therapeutic compounds to treat a wide range of diseases. Apellis Pharmaceuticals utilizes a targeted approach, specifically focusing on complement-mediated diseases such as paroxysmal nocturnal hemoglobinuria (PNH) and geographic atrophy (GA) associated with age-related macular degeneration (AMD). By researching and developing innovative treatments, Apellis Pharmaceuticals aims to address unmet medical needs and improve patients' quality of life. Apellis Pharmaceuticals Inc is dedicated to advancing the field of medicine through its commitment to research, development, and commercialization of cutting-edge therapies.
Apellis Pharmaceuticals Inc is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Apellis Pharmaceuticals Inc in the market include pharmaceutical companies such as Alexion Pharmaceuticals, Inc., Biogen Inc., and Genentech, Inc. Other major competitors in the biopharmaceutical industry include Novartis AG, Bristol-Myers Squibb Company, and Regeneron Pharmaceuticals, Inc.
Apellis Pharmaceuticals Inc, founded in 2009, is a global biopharmaceutical company focused on developing novel therapeutic compounds for treating various diseases. Headquartered in Waltham, Massachusetts, Apellis specializes in developing targeted therapies to address unmet medical needs. The company prioritizes innovative approaches and leverages its proprietary technology platforms to develop transformative therapies for patients. Apellis Pharmaceuticals Inc has a rich history of advancing drug candidates, with a particular emphasis on complement immunotherapy. With a dedicated team of scientists and industry experts, Apellis Pharmaceuticals Inc aims to make a significant impact on healthcare by offering potentially life-changing treatment options for patients worldwide.
Apellis Pharmaceuticals Inc has achieved several significant milestones. In 2019, the company received approval from the U.S. FDA for its first drug, Empaveli, as a treatment for paroxysmal nocturnal hemoglobinuria (PNH). This milestone marked a major breakthrough in the treatment of this rare blood disorder. Apellis Pharmaceuticals also expanded its clinical pipeline, with ongoing research and development in various therapeutic areas, including age-related macular degeneration and autoimmune diseases. The company continues to drive innovation through its commitment to advancing novel therapies and improving patient outcomes.
Apellis Pharmaceuticals Inc is primarily present in the United States, with its headquarters located in Waltham, Massachusetts. The company operates globally and has a strong presence across various countries and regions. Apellis Pharmaceuticals Inc has expanded its reach to other regions as well, including Europe, Asia-Pacific, and other international markets. With a commitment to developing innovative therapies, Apellis Pharmaceuticals Inc aims to improve the lives of patients worldwide through its presence in multiple countries and regions.
Apellis Pharmaceuticals Inc represents a commitment to improving the lives of patients by developing innovative and targeted therapies. The company's core values include integrity, collaboration, and a patient-centric approach. Apellis is dedicated to advancing medical science through groundbreaking research and development. With a focus on addressing unmet medical needs, Apellis strives to create value for shareholders while prioritizing the well-being of patients. By driving forward a corporate philosophy centered on scientific excellence and ethical practices, Apellis Pharmaceuticals Inc aims to make a positive impact in the healthcare industry.
Analysts currently set an average price target of 34.83 USD for the Apellis Pharmaceuticals stock (median: 32.13 USD), implying -15.1 % versus the latest price. The consensus is based on 28 analyst ratings.
28 analysts currently rate the Apellis Pharmaceuticals stock: 20 recommend buying, 7 holding and 1 selling. For 2026, analysts expect Apellis Pharmaceuticals to generate revenue of 871.41 M USD and earnings per share of -1.03 USD.
Converted at the current exchange rate, the Apellis Pharmaceuticals share trades at 36.82 EUR (41.03 USD).
The Apellis Pharmaceuticals share (APLS) is listed on 4 stock exchanges, including: NASDAQ (APLS), Frankfurt (1JK.F), München (1JK.MU), Düsseldorf (1JK.DU).
Apellis Pharmaceuticals Inc is an emerging biotechnology company focused on the development and commercialization of innovative therapies for rare medical needs. The business model of Apellis Pharmaceuticals is based on four core areas: research and development, clinical development, marketing, and business development.
The expected revenue of Apellis Pharmaceuticals is 871.41 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Apellis Pharmaceuticals is -130.02 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Apellis Pharmaceuticals is currently -39.77. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Apellis Pharmaceuticals stock.
The price-to-sales ratio (P/S) of Apellis Pharmaceuticals is currently 5.93. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Apellis Pharmaceuticals stock.
The Eulerpool Quality Score for Apellis Pharmaceuticals is 6/10.
The ISIN of Apellis Pharmaceuticals is US03753U1060. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Apellis Pharmaceuticals is A2JAAW. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Apellis Pharmaceuticals is APLS. The ticker symbol is used to trade Apellis Pharmaceuticals shares on the stock exchange.
Apellis Pharmaceuticals stock
Apellis Pharmaceuticals Peer Group
Apellis Pharmaceuticals Ticker
Apellis Pharmaceuticals FIGI
All fundamentals and in-depth analysis of Apellis Pharmaceuticals
Our stock analysis for Apellis Pharmaceuticals stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Apellis Pharmaceuticals. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.